^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Published date:
11/30/2023
Excerpt:
This study aims to propose a new biomarker to predict the response to Nivolumab in patients with ccRCC....In all three checkmates, OS and progression free survival (PFS) were found to be significantly higher in WDR72 high expression group than that in WDR72 low expression group (P=0.040 and P=0.012, respectively), and similar conclusions could be drawn from the PBRM1-mutation (MUT) compared with the PBRM1-wildtype (WT) (P=0.007 and P=0.006, respectively).
DOI:
https://doi.org/10.18632/aging.205261
Source:
Title:
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma
Published date:
10/06/2021
Excerpt:
In addition, PARP1 status was significantly associated with PFS (HR 2.6; p = 0.007) and OS (HR 3.5; p = 0.016) among patients with PBRM1-mutated ccRCC treated with nivolumab.
DOI:
10.1016/j.eururo.2021.09.024
Source:
Title:
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Excerpt:
...patients with metastatic ccRCC harboring truncating mutations in PBRM1 experienced increased clinical benefit from immune checkpoint therapy.
DOI:
10.1126/science.aan5951
Source:
Title:
1251P Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Excerpt:
Prior systemic therapy did not affect irPR or necrosis scores (p > 0.05, Fisher’s exact test). Patients positive for both an irPR score of 1 or 2 and PBRM1 mutation had significantly improved OS as compared to patients negative for both (median survival undefined vs. 7.9 months, log-rank p = 0.002).
DOI:
10.1093/annonc/mdz253.076
Trial ID:
